Coronavirus disease 2019 (COVID-19) has caused a global pandemic in just a few months,
causing millions infected. Nearly 20% of COVID-19 patients present severe coagulation …

Background Optimal dosing of the recombinant tissue-type plasminogen activator (rt-PA) is
important in treating pulmonary thromboembolism (PTE). The aim of this study was to …

Objective To evaluate pulmonary function and clinical symptoms in coronavirus disease 2019
(COVID-19) survivors within 3 months after hospital discharge, and to identify risk factors …

COVID-19 is also manifested with hypercoagulability, pulmonary intravascular coagulation,
microangiopathy, and venous thromboembolism (VTE) or arterial thrombosis. Predisposing …

Background There has not been sufficient evidence to support the Asians being less susceptible
to pulmonary embolism (PE) than other ethnicities, because the prevalence of PE/deep …

Background Measures of ventilatory efficiency during cardiopulmonary exercise testing (CPX)
are increasingly being used as prognostic markers in heart failure and pulmonary …

China, as accompanying more severe COVID-19 patient cases. We sought to determine the
accuracy of normal versus elevated D-dimer blood levels at presentation, on day 1, and on …

BACKGROUND The risk of VTE before anticancer therapy in patients with lung cancer is not
well defined. METHODS A total of 673 hospitalized patients with newly diagnosed lung …

Objectives To take advantage of the deep learning algorithms to detect and calculate clot
burden of acute pulmonary embolism (APE) on computed tomographic pulmonary …

Background Early identification and treatment of chronic thromboembolic pulmonary
hypertension (CTEPH) are critical to prevent disease progression. We determined the incidence …